20 percent more patients were treated with proton therapy in 2019
An individual eye shield is made for each patient to protect the surrounding tissue from the proton beam. © HZB
Number of patients who received the proton therapy offered jointly by Charité and HZB. © HZB/J. Politt
For more than 20 years, Charité - Universitätsmedizin Berlin and the Helmholtz-Zentrum Berlin (HZB) have jointly offered the irradiation of eye tumors with protons. In 2019, more patients were treated in Berlin-Wannsee than ever before. 276 patients - 20 percent more than in the previous year - underwent proton therapy. The treatment is specialized in choroidal melanomas of the eye. The proton accelerator at HZB is the only treatment facility for this disease in Germany.
500 to 600 people in Germany are affected by a malignant choroidal melanoma every year. In 97 percent of cases, the tumour can be completely destroyed by irradiation with protons. In most cases, not only the eye but also the vision can be maintained to a satisfactory degree. "The energy of the proton beam can be adjusted in such a way that practically only the tumor receives the radiation. Since the protons have a straight trajectory, the lateral scattering is much less than with X-rays," explains Dr. Jens Heufelder, the senior medical physicist at Charité - Universitätsmedizin Berlin. The protons effectively destroy the tumor, while the surrounding healthy tissue is largely spared.
To cope with the increase in patients in 2019, treatment operations at the proton accelerator have been extended to 12 hours. Approximately 45 percent of the patients came from the Berlin-Brandenburg region, the other patients came from other German states and other European countries (approximately 8 percent). The youngest patient who received proton therapy at HZB in 2019 was 8 years old, the oldest patient 96 years old. The average age was 61 years.
Since 1998, more than 3,700 patients have been treated with protons from the HZB accelerator. "The success of proton therapy is based on the collaboration between ophthalmologists, medical physicists and accelerator experts. As a result, the therapy has been continuously improved for the benefit of patients over the past few years", explains Prof. Dr. Andrea Denker, head of proton therapy at HZB.
- How carbonates influence CO2-to-fuel conversionResearchers from the Helmholtz Zentrum Berlin (HZB) and the Fritz Haber Institute of the Max Planck Society (FHI) have uncovered how carbonate molecules affect the conversion of CO2 into valuable fuels on gold electrocatalysts. Their findings reveal key molecular mechanisms in CO2 electrocatalysis and hydrogen evolution, pointing to new strategies for improving energy efficiency and reaction selectivity.
- Peat as a sustainable precursor for fuel cell catalyst materialsIron-nitrogen-carbon catalysts have the potential to replace the more expensive platinum catalysts currently used in fuel cells. This is shown by a study conducted by researchers from the Helmholtz-Zentrum Berlin (HZB), Physikalisch-Technische Bundesanstalt (PTB) and universities in Tartu and Tallinn, Estonia. At BESSY II, the team observed the formation of complex microstructures within various samples. They then analysed which structural parameters were particularly important for fostering the preferred electrochemical reactions. The raw material for such catalysts is well decomposed peat.
- Susanne Nies appointed to EU advisory group on Green DealDr. Susanne Nies heads the Green Deal Ukraina project at HZB, which aims to support the development of a sustainable energy system in Ukraine. The energy expert has now also been appointed to the European Commission's scientific advisory group to comment on regulatory burdens in connection with the net-zero target (DG GROW).